Thinkstock
Industryweek 7616 Gavel T

Thalidomide Manufacturer Wins Appeal in Spain Compensation Case

Oct. 22, 2014
Madrid's provincial court said the statute of limitations for the case against German pharmaceutical company Grunenthal had expired.

MADRID - A Spanish court has upheld an appeal by the German maker of the banned pregnancy drug thalidomide and scrapped a previous ruling ordering the firm to compensate Spaniards who suffered birth defects from it in the 1960s.

In the ruling reached Oct. 13 but only announced on Wednesday, Madrid's provincial court said the statute of limitations for the case against German pharmaceutical company Grunenthal had expired.

In November 2013 a lower court had ordered the firm to pay 20,000 euros ($25,500) for each percentage point of disability suffered by the victims as recognized by Spain's health ministry.

It did not specify exactly how many plaintiffs there were nor how much the compensation and costs would add up to in total.

The case was brought forward in 2012 by Avite, an association representing Spaniards born with severe defects after their mothers took the drug during their pregnancies.

We won the first assault, and they have won the second. The final outcome is missing."

— Avite association

Avite now has 20 days to appeal the court ruling and in a statement said its legal department was already studying its options.

"We cannot hide our huge disappointment and sadness," the group said.

"In this fight of David against Goliath, this was one of the possible outcomes, but far from discouraging this group, we believe that this is only a technical draw. We won the first assault, and they have won the second. The final outcome is missing."

Thalidomide was originally marketed as a sedative, but from the late 1950s was prescribed to women around the world to combat morning sickness.

Many of the children of the mothers who took the drug were born with abnormally short limbs and in some cases without any arms, legs or hips.

In late 1961 the drug was withdrawn from the British and German markets, but it continued to be sold in other countries including Spain, Canada and Japan for several more months.

The drug is estimated to have caused deformities in 10,000 to 20,000 babies in some 40 countries.

Avite estimates that up to 3,000 babies may have been born with deformities in Spain because of the drug.

It had sought compensation of 204 million euros for its members.

Dozens of Spaniards born with defects caused by thalidomide, many in wheelchairs or on crutches, attended the trial in Madrid last year. Grunenthal apologized in 2012.

Copyright Agence France-Presse, 2014

Popular Sponsored Recommendations

The Manufacturer's Guide to Transforming the Service Experience.

Sept. 11, 2023
Learn how a unified data platform can make your service experiences more efficient while reducing costs. Turn your service center into a profit center and map your service transformatio...

Beware Extreme Software

Sept. 24, 2023
As a manufacturer, you understand the importance of staying ahead of the curve and being proactive in your approach to technology. With the rapid pace of change in the industry...

Shifting Your Business from Products to Service-Based Business Models: Generating Predictable Revenues

Oct. 27, 2023
Executive summary on a recent IndustryWeek-hosted webinar sponsored by SAP

How to Build Zero-Cost On-Site Solar and Storage Projects

Nov. 25, 2023
The Inflation Reduction Act offers tax credits, incentives, and financing that enable no-cost projects. In Enel’s eBook, discover the critical role that incentives play in your...

Voice your opinion!

To join the conversation, and become an exclusive member of IndustryWeek, create an account today!